Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2018; 18(1):1-5
DOI: 10.5428/pcar20180101
Option of drugs for treatment of advanced gastric cancer
1. LI KaiChun1(1.Department of Oncology,Tianyou Hospital Affiliated to Tongji University,Shanghai 200331,China
2. LI Ping2(2.Department of Gastroenterology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China
ABSTRACT  Despite great progress in the treatment of gastric cancer in recent years,gastric cancer is still the third leading cause of cancer death worldwide.Cytoxic drugs including fluoropyrimidines,taxanes,the third generation platinum-based drugs and topoisomerase Ⅰ inhibitors have been applied in clinical treatment of gastric cancer.They can improve quality of life and prolong overall survival time of the patients.However,there still exist such shortfalls as relatively short survival time and adverse drug reactions.Following deeper understanding of the development and progress of gastric cancer,new targeted drugs such as trastuzumab,ramucirumab and apatinib have been applied in clinical use.In this paper,the option of drugs for the treatment of advanced gastric cancer is summarized and reviewed.
Welcome to PCAR! You are the number 463 reader of this article!
Please cite this article as:
LI KaiChun1,LI Ping2,. Option of drugs for treatment of advanced gastric cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(1): 1-5.
1. Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2. Chen W,Zheng R,Zeng H,et al.Annual report on status of cancer in China,2011[J].Chin J Cancer Res,2015,27(1):2-12.
3. Wagner A D,Grothe W,Haerting J,et al.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
4. GASTRIC(Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group,Oba K,Paoletti X,et al.Role of chemotherapy for advanced/recurrent gastric cancer:an individual-patient-data meta-analysis[J].Eur J Cancer,2013,49(7):1565-1577.
5. Bang Y J,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
6. Kim T Y,Oh D Y,Bang Y J.Capecitabine for the treatment of gastric cancer[J].Expert Rev Gastroenterol Hepatol,2015,9(12):1471-1481.
7. Ryu M H,Kang Y K.ML17032 trial:capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer[J].Expert Rev Anticancer Ther,2009,9(12):1745-1751.
8. Okines A F,Norman A R,McCloud P,et al.Meta-analysis of the REAL-2 and ML17032 trials:evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer[J].Ann Oncol,2009,20(9):1529-1534.
9. Chhetri P,Giri A,Shakya S,et al.Current development of anti-cancer drug S-1[J].J Clin Diagn Res,2016,10(11):XE01-XE05.
10. Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.
11. Ajani J A,Rodriguez W,Bodoky G,et al.Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28(9):1547-1553.
12. Gadgeel S M,Shields A F,Heilbrun L K,et al.Phase Ⅱ study of paclitaxel and carboplatin in patients with advanced gastric cancer[J].Am J Clin Oncol,2003,26(1):37-41.
13. Hironaka S,Ueda S,Yasui H,et al.Randomized,open-label,phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial[J].J Clin Oncol,2013,31(35):4438-4444.
14. van Cutsem E,Moiseyenko V M,Tjulandin S,et al.Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991-4997.
15. Ajani J A.Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction:evolution of the docetaxel,cisplatin,and 5-fluorouracil regimen[J].Cancer,2008,113(5):945-955.
16. Cunningham D,Starling N,Rao S,et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].N Engl J Med,2008,358(1):36-46.
17. Dank M,Zaluski J,Barone C,et al.Randomized phase Ⅲ study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction[J].Ann Oncol,2008,19(8):1450-1457.
18. Croxtall J D,McKeage K.Trastuzumab:in HER2-positive metastatic gastric cancer[J].Drugs,2010,70(17):2259-2267.
19. Shen L,Xu J M,Feng F Y,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer:a Phase Ⅲ,multi-center,randomized controlled trial,Chinese subreport[J].Chin J Oncol,2013,35(4):295-300.
20. Sawaki A,Ohashi Y,Omuro Y,et al.Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer:a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA) study[J].Gastric Cancer,2012,15(3):313-322.
21. Poole R M,Vaidya A.Ramucirumab:first global approval[J].Drugs,2014,74(9):1047-1058.
22. Fuchs C S,Tomasek J,Yong C J,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383(9911):31-39.
23. Wilke H,Muro K,Van Cutsem E,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase 3 trial[J].Lancet Oncol,2014,15(11):1224-1235.
24. Casak S J,Fashoyin-Aje I,Lemery S J,et al.FDA approval summary:ramucirumab for gastric cancer[J].Clin Cancer Res,2015,21(15):3372-3376.
25. Brower V.Apatinib in treatment of refractory gastric cancer[J].Lancet Oncol,2016,17(4):e137.
26. Li J,Qin S,Xu J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.
27. Li J,Qin S,Xu J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
28. Li K,Li J.Current molecular targeted therapy in advanced gastric cancer:a comprehensive review of therapeutic mechanism,clinical trials,and practical application[J].Gastroenterol Res Pract,2016,2016(9742):1-9.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330